Characteristics of patients with RA. Values are the mean ± SD unless otherwise specified.
| Characteristics | n = 75 |
|---|---|
| Disease duration, yrs | 12.9 ± 9.2 |
| Positive for RF (%) | 48 (64.0) |
| Positive for anti-CCP (%) | 50 (66.6) |
| Erosive arthritis (%) | 44 (56.8) |
| Rheumatoid nodules (%) | 16 (21.3) |
| Tender joint count, 28 joints | 1.9 ± 3.2 |
| Swollen joint count, 28 joints | 1.7 ± 2.6 |
| HAQ score | 1.0 ± 0.7 |
| DAS28-hs-CRP | 2.7 ±1.0 |
| DAS28-hs-CRP ≤ 3.2 (%) | 54 (72.0) |
| Current cs-DMARD users (%) | 62 (82.6) |
| Current methotrexate users (%) | 57 (76.0) |
| Dose of methotrexate used, mg/week | 13.2 ± 4.6 |
| Current bDMARD users (%) | 50 (66.6) |
| Current anti-TNF-α users (%) | 31 (41.3) |
| Current NSAID users (%) | 21 (28.0) |
| Current GC users (%) | 22 (29.3) |
| Dose of GC used, mg/day | 5.7 ± 2.1 |
RA: rheumatoid arthritis; RF: rheumatoid factor; anti-CCP: anticyclic citrullinated peptide; HAQ: Health Assessment Questionnaire; DAS28-hs-CRP: Disease Activity Score 28-high-sensitivity C-reactive protein; cs-DMARD: conventional synthetic disease-modifying antirheumatic drug; bDMARD: biologic DMARD; TNF-α: tumor necrosis factor-α; NSAID: nonsteroidal antiinflammatory drug; GC: glucocorticoid.